Late Toxicity in High-risk Prostate Cancer Treated with Androgen Suppression and Hypofractionated Intensity Modulated Radiotherapy

被引:1
|
作者
Drodge, S. [1 ]
Pervez, N. [1 ]
Ghosh, S. [1 ]
Mackenzie, M. [1 ]
Yee, D. [1 ]
Mihai, A. [1 ]
Murtha, A. [1 ]
Amanie, J. [1 ]
Fallone, G. [1 ]
Pearcey, R. [1 ]
机构
[1] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
关键词
D O I
10.1016/j.ijrobp.2010.07.834
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:S353 / S353
页数:1
相关论文
共 50 条
  • [1] Acute and Late Toxicity in High-risk Prostate Cancer Treated with Androgen Suppression and Hypofractionated Intensity Modulated Radiotherapy
    Le, D.
    Drodge, C. S.
    Pervez, N.
    Ghosh, S.
    Yee, D.
    Parliament, M.
    Murtha, A.
    Amanie, J.
    MacKenzie, M.
    Pearcey, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S101 - S101
  • [2] ACUTE TOXICITY IN HIGH-RISK PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN SUPPRESSION AND HYPOFRACTIONATED INTENSITY-MODULATED RADIOTHERAPY
    Pervez, Nadeem
    Small, Cormac
    MacKenzie, Marc
    Yee, Don
    Parliament, Matthew
    Ghosh, Sunita
    Mihai, Alina
    Amanie, John
    Murtha, Albert
    Field, Colin
    Murray, David
    Fallone, Gino
    Pearcey, Robert
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (01): : 57 - 64
  • [3] Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiotherapy.
    Faria, Sergio
    Ruo, Russel
    Cury, Fabio
    Duclos, Marie
    Souhami, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [4] ACUTE AND LATE TOXICITY IN HIGH-RISK PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN SUPPRESSION AND HYPOFRACTIONATED RADIOTHERAPY (HYPORT) TO THE PROSTATE AND PELVIC NODES
    Faria, Sergio
    Petrucelli, Mariana
    Cury, Fabio
    Duclos, Marie
    Souhami, Luis
    RADIOTHERAPY AND ONCOLOGY, 2016, 120 : S21 - S21
  • [5] HYPOFRACTIONATED CONCOMITANT INTENSITY-MODULATED RADIOTHERAPY BOOST FOR HIGH-RISK PROSTATE CANCER: LATE TOXICITY
    Quon, Harvey
    Cheung, Patrick C. F.
    Loblaw, D. Andrew
    Morton, Gerard
    Pang, Geordi
    Szumacher, Ewa
    Danjoux, Cyril
    Choo, Richard
    Thomas, Gillian
    Kiss, Alex
    Mamedov, Alexandre
    Deabreu, Andrea
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (02): : 898 - 905
  • [6] Clinical outcomes and late toxicity of hypofractionated intensity-modulated radiotherapy for high-risk prostate cancer.
    Wang, Michael
    Pearcey, Robert
    Pervez, Nadeem
    Yee, Don
    Mihai, Alina
    Patel, Samir
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [7] Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy
    Faria, Sergio
    Ruo, Russel
    Cury, Fabio
    Duclos, Marie
    Souhami, Luis
    PRACTICAL RADIATION ONCOLOGY, 2017, 7 (04) : 264 - 269
  • [8] Hypofractionated Intensity Modulated Radiation Therapy to Prostate and Pelvic Nodes Plus Androgen Suppression in High-Risk Prostate Cancer
    Faria, S. L.
    Cury, F.
    Duclos, M.
    Souhami, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S146 - S146
  • [9] Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity
    Thomson, David
    Merrick, Sophie
    Swindell, Ric
    Coote, Joanna
    Kelly, Kay
    Stratford, Julie
    Wylie, James
    Cowan, Richard
    Elliott, Tony
    Logue, John
    Choudhury, Ananya
    Livsey, Jacqueline
    PROSTATE CANCER, 2012, 2012
  • [10] Late Toxicity and Outcomes in High-risk Prostate Cancer Patients Treated With Hypofractionated IMRT and Long-term Androgen Suppression Treatment
    Pervez, Nadeem
    Boychak, Alex
    Drodge, Claudia S.
    Yee, Don
    Le, Duc
    Murtha, Albert
    Parliament, Matthew
    Amanie, John
    Mihai, Alina
    Field, Colin
    Mackenzie, Marc
    Ghosh, Sunita
    Fallone, Gino
    Pearcey, Robert
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (02): : 200 - 206